• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by ObsEva SA

    4/26/23 7:00:50 AM ET
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OBSV alert in real time by email
    15-12G 1 d501337d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-37993

     

     

    OBSEVA SA

    (Exact name of registrant as specified in its charter)

     

     

    Chemin des Aulx, 12, Plan-les-Ouates, 1228, Geneva Switzerland

    + 41 22 552 38 40

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common shares, par value CHF 1/13 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☐

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date:

    Common shares, par value CHF 1/13 per share – 104

    Pursuant to the requirements of the Securities Exchange Act of 1934, ObsEva SA has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: April 26, 2023

       

    By:

     

    /s/ Will Brown

       

    Name:

     

    Will Brown

       

    Title:

     

    Interim Chief Executive Officer and Chief

    Financial Officer

     

     

     

    Get the next $OBSV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OBSV

    DatePrice TargetRatingAnalyst
    8/30/2022Buy → Neutral
    H.C. Wainwright
    6/3/2022$6.00Overweight
    Cantor Fitzgerald
    4/26/2022$12.00Buy
    Canaccord Genuity
    3/28/2022$12.00Buy
    Aegis Capital
    11/29/2021$17.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OBSV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ObsEva Files Year End 2022 Financial Statements

      ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20

      3/31/23 4:01:00 PM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd

      3/15/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

      Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

      3/13/23 7:00:00 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBSV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ObsEva downgraded by H.C. Wainwright

      H.C. Wainwright downgraded ObsEva from Buy to Neutral

      8/30/22 7:29:47 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ObsEva with a new price target

      Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00

      6/3/22 7:29:31 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on ObsEva with a new price target

      Canaccord Genuity initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00

      4/26/22 6:26:53 AM ET
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care